Accéder au contenu
Merck

Trimethoprim-sulfamethoxazole for bacterial meningitis.

Annals of internal medicine (1984-06-01)
R E Levitz, R Quintiliani
RÉSUMÉ

Trimethoprim-sulfamethoxazole has excellent microbiologic activity against most pathogens that produce meningitis; both components of this drug have high penetration into tissues, including the cerebrospinal fluid. Clinical experience shows that trimethoprim-sulfamethoxazole may be beneficial in the treatment of gram-negative bacillary meningitis caused by organisms only moderately susceptible to third-generation cephalosporins (Enterobacter cloacae, Serratia marcescens) or resistant to these antibiotic agents (Pseudomonas cepacia, Acinetobacter). The success of trimethoprim-sulfamethoxazole in the treatment of four patients with Staphylococcus aureus and two patients with Listeria monocytogenes meningitis shows that this drug may also be useful in treating infrequent types of gram-positive meningitis.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Supelco
Sulfamethoxazole
USP
Sulfamethoxazole, United States Pharmacopeia (USP) Reference Standard
Supelco
Sulfamethoxazole, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Sulfamethoxazole, VETRANAL®, analytical standard
Sulfamethoxazole, European Pharmacopoeia (EP) Reference Standard
Supelco
Sulfamethoxazole, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland